🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)A1C reduction on semaglutide: SUSTAIN program meta-analysis

A1C reduction on semaglutide: SUSTAIN program meta-analysis

A1cHero_PHX Tue, May 19, 2026 at 4:00 AM 22 replies 520 viewsPage 1 of 5
A1cHero_PHX
Member
523
2,678
Jul 2024
Phoenix, AZ
May 19, 2026 at 4:00 AM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

The bit I cannot resolve on my own is whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
35 5zoe_NC, Dr.ObesityLA, NurseKim_ATL and 32 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
May 19, 2026 at 4:05 AM#2
A1cHero_PHX said:
Steady state is the thing most people miss.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

34 4stefan_berlin, Dr.EM_Chicago, pete_RVA and 31 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
May 19, 2026 at 4:10 AM#3
A1cHero_PHX said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: May 19, 2026 at 6:10 AM
33 3LibrarianMeg, bri_stats, pete_manc_UK and 30 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
May 19, 2026 at 4:14 AM#4

Taking the question as asked, rather than the general version of it. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

32 2Admin, Dr.Martinez, mike_mod and 29 others
Reply Quote Save Share Report
sarah_nash92
Member
712
3,123
Jun 2024
Nashville, TN
May 19, 2026 at 4:40 AM#5
TrialTracker_MD said:
Agreed, though "tolerable" needs defining.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

31 1KetoKyle, CanadaChris, ZaraB_AL and 28 others
Reply Quote Save Share Report
1235

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register